CDH Investments-backed Chinese biopharmaceutical firm Mabpharm has joined a list of biotech firms seeking to raise capital through a listing in Hong Kong, which recently relaxed rules to allow biotech companies with no revenue to go public.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
